

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6913620

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NOVASEP PROCESS	09/10/2021
RECEIVING PARTY DATA		
Name:	NOVASEP EQUIPMENT SOLUTIONS	
Street Address:	SITE EIFFEL	
Internal Address:	BOULEVARD DE LA MOSELLE	
City:	POMPEY	
State/Country:	FRANCE	
Postal Code:	54340	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	16155646
	Application Number:	16340041
CORRESPONDENCE DATA		
Fax Number:	(978)341-0136	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	9783410036	
Email:	lisa.puopolo@hbsr.com	
Correspondent Name:	SUSAN G. L. GLOVSKY	
Address Line 1:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.	
Address Line 2:	530 VIRGINIA ROAD, P.O. BOX 9133	
Address Line 4:	CONCORD, MASSACHUSETTS 01742-9133	
ATTORNEY DOCKET NUMBER:	5384.0000-000	
NAME OF SUBMITTER:	LISA PUOPOLO	
SIGNATURE:	/Lisa Puopolo/	
DATE SIGNED:	09/13/2021	
Total Attachments: 4		
source=NOV.02845.RG2-2021.09#page1.tif		
source=NOV.02845.RG2-2021.09#page2.tif		
source=NOV.02845.RG2-2021.09#page3.tif		

Patent Assignment

Between:

NOVASEP PROCESS
Site Eiffel
Boulevard de la Moselle
54340 Pompey
France
(hereafter "*The Assignor*")

And:

NOVASEP EQUIPMENT SOLUTIONS
Site Eiffel
Boulevard de la Moselle
54340 Pompey
France
(hereafter "*The Assignee*")

WHEREAS, the Assignor and the Assignee have entered into an agreement dated March 30, 2021 for the transfer of certain assets (hereafter the "*Transfer Agreement*"), pursuant to which the Assignor has agreed, among other things, to transfer to the Assignee all of the Assignor's right, title and interest in and to, among other things, patents and other intellectual property, including the Assigned Patents (as defined below); and

WHEREAS, the Assignor and the Assignee execute this Patent Assignment to transfer the Assigned Patents, and among other things, for purposes of recording the assignment of the Assigned Patents and filing this Patent Assignment with any administrative body worldwide, including to indicate ownership of the intellectual property described below.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor and Assignee hereby agree as follows:

1. Assignment and Transfer.

Effective May 5, 2021, the Assignor hereby irrevocably and forever, without reservation, sells, assigns, conveys, transfers and delivers to the Assignee the Assignor's entire right, title and interest throughout the world in, to and under the patents, patent applications, utility models and/or utility model applications listed in annex, and the inventions and other proprietary information disclosed, described, embodied or claimed therein (the "*Assigned Patents*"), the same to be held and enjoyed by the Assignee for its own use and enjoyment and the use and enjoyment of its successors, assigns and other legal representatives to the full end of the term or terms for which patents or other rights may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignor if this assignment had not been made and the Assignee hereby accepts from the Assignor and succeeds to the Assigned Patents, including (a) all applications or counterparts in any jurisdiction pertaining to any of the foregoing, including applications filed pursuant to any international patent law treaty, including all national parts of European patents, all PCT national phase or regional phase entries, together with


ev

all worldwide rights and priorities afforded under any law with respect to any of the foregoing, and any other patents, applications or extensions that claim priority to or through any of the foregoing, and any inventions or other proprietary information disclosed, described, embodied or claimed in any of the foregoing; (b) continuations, continuations-in-part, divisionals, reissues, re-examinations, renewals, confirmations, substitutions and extensions thereof or related thereto; (c) all other rights of any kind whatsoever, whether statutory, common law or otherwise, in, arising out of, or associated with the foregoing in any jurisdiction worldwide, including those arising under international treaties and convention rights; (d) all rights and powers to assert, defend and recover title to any of the foregoing; (e) all rights to assert, defend, sue, and recover damages for any past, present and future infringement, misuse, misappropriation, impairment, unauthorized use or other violation of any rights in or to any of the foregoing; (f) all proceeds, income, royalties, damages and payments now or hereafter due and payable under or in respect of all of the foregoing (including with respect to past, present or future infringement or violation thereof); and (g) all administrative rights arising from the foregoing, including the right to file and prosecute applications and oppose, interfere with or challenge the applications of others and obtain legal protection pertaining to any of the foregoing.


2. Terms of the Transfer Agreement.

None of the representations, warranties, covenants, obligations, rights or remedies of any party under the Transfer Agreement shall be deemed to be limited, qualified, enlarged, modified or altered in any way by the execution, delivery or acceptance of this Patent Assignment. In the event of any conflict or inconsistency between the terms of the Transfer Agreement and the terms hereof, the terms of the Transfer Agreement shall govern.

Signed on behalf of the ASSIGNOR:

Date: 12/13/2011
 Name: ERIC VALERY
 Position: IP DIRECTOR
 Place: LYON
 Signature: 

Signed on behalf of the ASSIGNEE:

Date: 12/13/2011
 Name: ERIC VALERY
 Position: IP DIRECTOR
 Place: LYON
 Signature: 

Annex – list of Assigned Patents

Publication or grant or registration No.	Application or filing No.	Priority date
FR2897277	FR0601199	10.02.2006
EP2062043	EP07823443.2	23.08.2007
CN206262156 U	CN2016211612951.1	01.11.2016
WO2018073500	PCT/FR2016/052725	21.10.2016
ID2019/07469	PID201902689	21.10.2016
	TH1901001930	21.10.2016
	MYPI2019001914	21.10.2016
US2020/030718	US16/340041	21.10.2016
CA3039158	CA3039158	21.10.2016
WO201556237	PCT/IB2014/065412	17.10.2014
SG10201811186X	SG10201811186X	17.10.2014
CN106029690	CN201480069196.8	17.10.2014
EP3057987	EP14802170.2	17.10.2014
KR10-2016-0078994	KR10-2016-7012940	17.10.2014
SG112016030285	SG112016030285	17.10.2014
US2016/272675 US10508133	US15/029682	17.10.2014
	IN201647016722	17.10.2014
FR3099066	FR1908574	26.07.2019
WO2021/019167A1	PCT/FR2020/051360	26.07.2019
US6533940	US09/892796	28.06.2000
	FR2011556	10.11.2020
	EP20306241	19.10.2020
FR3014435	FR1362443	11.12.2013
WO2015086591	PCT/EP2014/077036	11.12.2013
CA2932932	CA2932932	11.12.2013
CN105848747	CN201480071042.2	11.12.2013
EP3079787	EP14809046.7	11.12.2013
JP2017504683A JP6467426	JP2016539175	11.12.2013
KR10-2016-0096627	KR10-2016-7016793	11.12.2013
US2016/304433 US9802881	US15/102706	11.12.2013
CL2016001395	CL2016001395	11.12.2013
	IN201617023191	11.12.2013
FR3014436	FR1362444	11.12.2013
WO201586607	PCT/EP2014/077067	11.12.2013
CA2932929	CA2932929	11.12.2013
CN105848748	CN201480071100.1	11.12.2013
EP3079788	EP14815609.4	11.12.2013
EP3473318	EP18209325.2	11.12.2013
JP2017504472 JP6581090	JP2016539184	11.12.2013
KR10-2016-0096110	KR10-2016-7016797	11.12.2013

EV

Publication or grant or registration No.	Application or filing No.	Priority date
US2016/311750 US9802882	US15/102796	11.12.2013
CL2016001397	CL2016001397	11.12.2013
IN330112	IN201617021785	11.12.2013
US20200108044	US16/155646	09.10.2018
WO2020074453	PCT/EP2019/077106	09.10.2018
	EP19786300.4	09.10.2018
	CA3112899	09.10.2018
	IL282035	09.10.2018
FR2889077	FR0507952	26.07.2005
WO2007012750	PCT/FR2006/001812	26.07.2005
CN101272838	CN200680035285.6	26.07.2005
EP1912716	EP06794211.0	26.07.2005
US2011/0168632 US9180387	US11/996840	26.07.2005
IN281555	726/DELNP/2008	26.07.2005
FR2898283	FR0602076	08.03.2006
WO2007101944	PCT/FR2007/000406	08.03.2006
EP2024049	EP07731104.1	08.03.2006
US2011/0000853 US8216475	US12/281170	08.03.2006
IN293028	1935/MUMNP/2008	08.03.2006
WO2007144476	PCT/FR2006/001373	16.06.2007
WO2007144522	PCT/FR2007/001012	16.06.2007
EP2040811	EP07788903.8	16.06.2007
US2009/0209736 US8182696	US12/304840	16.06.2007
US2012214966 US8465649	US13/448959	16.06.2007
IN265269	2767/MUMNP/2008	16.06.2007
FR2929533	FR0801844	03.04.2008
WO2009122281	PCT/IB2009/005191	03.04.2008
CN102026695	CN200980117571.0	03.04.2008
EP2276548	EP09728317.0	03.04.2008
JP2011517489 JP5330499	JP2011502453	03.04.2008
US2011/030457 US8752417	US12/936319	03.04.2008
IN296200	6812/DELNP/2010	03.04.2008

2v